These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29084914)

  • 41. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
    Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
    Vencken PM; Reitsma W; Kriege M; Mourits MJ; de Bock GH; de Hullu JA; van Altena AM; Gaarenstroom KN; Vasen HF; Adank MA; Schmidt MK; van Beurden M; Zweemer RP; Rijcken F; Slangen BF; Burger CW; Seynaeve C
    Ann Oncol; 2013 Aug; 24(8):2036-42. PubMed ID: 23543211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
    Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
    Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
    Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
    Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients: Finding Founder Mutations.
    Choi MC; Heo JH; Jang JH; Jung SG; Park H; Joo WD; Lee C; Lee JH; Lee JM; Hwang YY; Kim SJ
    Int J Gynecol Cancer; 2015 Oct; 25(8):1386-91. PubMed ID: 26402875
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
    Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 48. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
    Dong F; Davineni PK; Howitt BE; Beck AH
    Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    Zaaijer LH; van Doorn HC; Mourits MJ; van Beurden M; de Hullu JA; Adank MA; van Lonkhuijzen LR; Vasen HF; Slangen BF; Gaarenstroom KN; Zweemer RP; Vencken PM; Seynaeve C; Kriege M
    Br J Cancer; 2016 Nov; 115(10):1174-1178. PubMed ID: 27755534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?
    Reitsma W; de Bock GH; Oosterwijk JC; ten Hoor KA; Hollema H; Mourits MJ
    Int J Gynecol Cancer; 2012 May; 22(4):579-85. PubMed ID: 22274543
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
    Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
    Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
    Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
    Kadouri L; Rottenberg Y; Zick A; Hamburger T; Lipson D; Peretz T; Nechushtan H
    Lung Cancer; 2019 Nov; 137():48-51. PubMed ID: 31542568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
    Rebbeck TR; Mitra N; Domchek SM; Wan F; Chuai S; Friebel TM; Panossian S; Spurdle A; Chenevix-Trench G; ; Singer CF; Pfeiler G; Neuhausen SL; Lynch HT; Garber JE; Weitzel JN; Isaacs C; Couch F; Narod SA; Rubinstein WS; Tomlinson GE; Ganz PA; Olopade OI; Tung N; Blum JL; Greenberg R; Nathanson KL; Daly MB
    Cancer Res; 2009 Jul; 69(14):5801-10. PubMed ID: 19584272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
    Lavie O; Chetrit A; Novikov I; Sadetzki S;
    Gynecol Oncol; 2019 May; 153(2):320-325. PubMed ID: 30872026
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Ramus SJ; Antoniou AC; Kuchenbaecker KB; Soucy P; Beesley J; Chen X; McGuffog L; Sinilnikova OM; Healey S; Barrowdale D; Lee A; Thomassen M; Gerdes AM; Kruse TA; Jensen UB; Skytte AB; Caligo MA; Liljegren A; Lindblom A; Olsson H; Kristoffersson U; Stenmark-Askmalm M; Melin B; ; Domchek SM; Nathanson KL; Rebbeck TR; Jakubowska A; Lubinski J; Jaworska K; Durda K; Złowocka E; Gronwald J; Huzarski T; Byrski T; Cybulski C; Toloczko-Grabarek A; Osorio A; Benitez J; Duran M; Tejada MI; Hamann U; Rookus M; van Leeuwen FE; Aalfs CM; Meijers-Heijboer HE; van Asperen CJ; van Roozendaal KE; Hoogerbrugge N; Collée JM; Kriege M; van der Luijt RB; ; ; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Lalloo F; Jacobs C; Eeles R; Adlard J; Davidson R; Eccles D; Cole T; Cook J; Paterson J; Douglas F; Brewer C; Hodgson S; Morrison PJ; Walker L; Porteous ME; Kennedy MJ; Pathak H; Godwin AK; Stoppa-Lyonnet D; Caux-Moncoutier V; de Pauw A; Gauthier-Villars M; Mazoyer S; Léoné M; Calender A; Lasset C; Bonadona V; Hardouin A; Berthet P; Bignon YJ; Uhrhammer N; Faivre L; Loustalot C; ; Buys S; Daly M; Miron A; Terry MB; Chung WK; John EM; Southey M; Goldgar D; Singer CF; Tea MK; Pfeiler G; Fink-Retter A; Hansen Tv; Ejlertsen B; Johannsson OT; Offit K; Kirchhoff T; Gaudet MM; Vijai J; Robson M; Piedmonte M; Phillips KA; Van Le L; Hoffman JS; Ewart Toland A; Montagna M; Tognazzo S; Imyanitov E; Issacs C; Janavicius R; Lazaro C; Blanco I; Tornero E; Navarro M; Moysich KB; Karlan BY; Gross J; Olah E; Vaszko T; Teo SH; Ganz PA; Beattie MS; Dorfling CM; van Rensburg EJ; Diez O; Kwong A; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ditsch N; Arnold N; Heidemann S; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Fiebig B; Schäfer D; Caldes T; de la Hoya M; Nevanlinna H; Aittomäki K; Plante M; Spurdle AB; ; Neuhausen SL; Ding YC; Wang X; Lindor N; Fredericksen Z; Pankratz VS; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Bonanni B; Bernard L; Dolcetti R; Papi L; Ottini L; Radice P; Greene MH; Mai PL; Andrulis IL; Glendon G; Ozcelik H; ; Pharoah PD; Gayther SA; Simard J; Easton DF; Couch FJ; Chenevix-Trench G;
    Hum Mutat; 2012 Apr; 33(4):690-702. PubMed ID: 22253144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    Tsibulak I; Wieser V; Degasper C; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Marth C; Fiegl H; Zeimet AG
    Br J Cancer; 2018 Sep; 119(6):683-692. PubMed ID: 30111871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.